Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for
|
|
- Branden Stevenson
- 6 years ago
- Views:
Transcription
1 Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for Inoperable Stage II-IIIB NSCLC 1
2 Co-Chairs Study Chair: Zhongxing Liao, MD Radiation Oncology: Jeffrey Bradley, MD, Washington University Noah Choi, MD, Massachusetts General Hospital Steven Hahn, MD, University of Pennsylvania Ritsuko Komaki, MD, MD Anderson Cancer Center Brad Hoppe, MD, University of Florida Eugen Hug, MD, ProCure Medical Oncology: Charles Lu, MD, MD Anderson Medical Physics: Michael Gillin, PhD, MD Anderson Radhe Mohan, PhD, MD Anderson Translational Research: Steven H. Lin, MD, PhD, MD Anderson Quality of Life: Xin Shelley Wang, MD, MD Anderson Outcomes: Ben Movsas, MD, Henry Ford Health System Comparative Cost Effectiveness: Deborah Bruner, RN, PhD, Emory University Gregory Russo, MD, Boston University School of Medicine 2
3 Specific hypotheses When standard constraints on radiation dose and volume to organs at risk (OARs) are used, proton beam therapy will allow lower doses to critical organs and higher doses to be delivered to the target compared with photons, which will result in an improvement of median survival time from 21 months (control arm) to 28 months (proton arm) in patients with good performance status and stage II-IIIB non-small cell lung cancer (NSCLC).
4 RTOG 1308 Schema S T R A T I F Y Stage 1.II 2.IIIA 3.IIIB Histology 1.Squamous 2.Non Squamous Concurrent Chemotherapy Doublet Type 1.Carboplatin/paclitaxel 2.Cisplatin/etoposide R A N D O M I Z E Arm 1: Photon dose 70 Gy*, at 2 Gy (RBE) once daily plus platinumbased doublet chemotherapy** Arm 2: Proton dose 70 Gy (RBE), at 2 Gy once daily plus platinumbased doublet chemotherapy** Both Arms: Consolidation chemotherapy x 2cycles required for patients who receive concurrent carboplatin and paclitaxel*** *The total prescribed dose will be 70 Gy (Relative Biological Effectiveness (RBE)) without exceeding tolerance dose-volume limits of all critical normal structures. (See Section when 70 Gy (RBE) is not achieved) **Chemotherapy delivered concurrently, cisplatin/ etoposide or carboplatin/paclitaxel doublets,isrequired. The site/investigator must declare the chemotherapy regimen that the patient will receive prior to the patient s randomization.see Section 7.0 for details. ***If carboplatin and paclitaxel is administered concurrently with radiotherapy, 2 cycles of carboplatin and paclitaxel consolidation chemotherapy are required. If cisplatin and etoposide is administered concurrently with radiotherapy, consolidation chemotherapy is not allowed. 4
5 Primary Objective To compare the overall survival (OS) in patients with stage II-IIIB NSCLC after image guided, motionmanaged photon radiotherapy (Arm 1) or proton radiotherapy (Arm 2) both given with concurrent platinum- based chemotherapy. Survival time is defined as the time from randomization to the date of death of any cause
6 Secondary Objectives To compare 2-year progression-free survival (PFS) between the 2 arms; To compare the development of grade 3 or higher adverse events definitely, probably, or possibly related to treatment (see Section 13.2 for specific adverse events). To compare the development of patient-reported outcome symptom burden [MDASI-Lung]), Shortness Breath Questionnaire [SOBQ] Health utility EuroQol [EQ5D] To compare cost-effectiveness outcomes To compare pulmonary function changes by treatment arms and response; To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness (imaging, simulation, immobilization, target and critical structure definition, treatment planning, image guidance and delivery).
7 Registration Credentialing Dry run Overall Flow Diagram Enrollment and randomization Radiation Treatment planning Eligibility, IC, PRO, Optional blood Sim and motion management Target Delineation Dose constraints Tumor dose prescriptions Yes Adaptive Planning? Quick review of the plans 1. First (re)plans; 2. Tumor dose <70 Gy Treatment Repeat CT x 2 Weekly AE Wk 4 blood Wk 6 PROs Follow ups 7
8 Registration Credentialing Dry run Overall Flow Diagram Enrollment and randomization Radiation Treatment planning Eligibility, IC, PRO, Optional blood Sim and motion Target Tumor dose Dose constraints management Registrations, sec. 5.0 Delineation : prescriptions Site staff registration with CTEP LOI to NRG (RTOG) Credentialing Yes RT specific pre registration requirements (sec Quick review of the plans ) Adaptive OPEN registration 1. First (re)plans; 2., or Tumor dose <70 Gy Planning? Treatment Repeat CT x 2 Weekly AE Wk 4 blood Wk 6 PROs Follow ups 8
9 Registration Credentialing Dry run Overall Flow Diagram Enrollment and randomization Radiation Treatment planning Eligibility, IC, PRO, Optional blood Patient selection: Refer to protocol sec. 3.0: Sim and motion For questions concerning Target eligibility, please Tumor dose Dose contact constraints RTOG Data Management (via the RTOG management contact list on the Delineation RTOG website) prescriptions Contact or additional? Pretreatment evaluations, protocol sec. 4.0 Informed Yes consent Quick review of the plans Adaptive PRO 1. First (re)plans; 2. Tumor dose <70 Gy Planning? Optional procedures Treatment Repeat CT x 2 Weekly AE Wk 4 blood Wk 6 PROs Follow ups 9
10 Overall Flow Diagram Enrollment and randomization Eligibility, IC, PRO, Optional blood Radiation Treatment planning Sim and motion management Target Delineation Dose constraints Tumor dose prescriptions Quick review of the plans (5 cases) Yes QA Adaptive Planning? Physics QA Peer review QA Treatment Repeat CT x 2 Weekly AE Wk 4 blood Wk 6 PROs Follow ups 10
11 Overall Flow Diagram Radiation Treatment planning Sim RADIATION and motion THERAPY: Target Refer to protocol Dose sec. 6.0: Tumor dose Quick review of the management Data submission: Delineation TRIAD constraints prescriptions plans (5 cases) Dose Specifications, protocol sec. 6.1 as follows: 1. Yes Plan prescription dose 70 Gy, if not QA meeting dose constraints, then 2. Reduce tumor dose 2 Gy each time, i.e. 68, 66, 64, 62, and 60 till dose constraints are met. Adaptive 3. If dose constraints can not be met at 60 Gy, patient Planning? Physics QA Peer review should QA be treated with the highest achievable dose, or start with induction chemotherapy if patient had not received induction chemotherapy Simulation, Immobilization, Motion Treatment Assessment, and Motion Management, sec. 6.3 Repeat CT x 2 Weekly AE Wk 6 PROs Follow ups Target Definitions, Target Delineation, and Normal Anatomy Delineation, sec 6.4 Required structures should we standardize the color? Optional procedures Wk 4 blood 11
12 Overall Flow Diagram Radiation Treatment planning Sim and motion Target Dose Tumor dose Quick review of the management Delineation constraints prescriptions plans (5 cases) RADIATION THERAPY: Refer to protocol sec. 6.0: Data submission: TRIAD Dose Yes Specifications, protocol sec. 6.1 QA as follows: 1. Plan prescription dose 70 Gy, if not meeting dose constraints, then Adaptive 2. Reduce tumor dose 2 Gy each time, i.e. 68, 66, 64, 62, and 60 till dose constraints are Planning? met. Physics QA Peer review QA 3. If dose constraints can not be met at 60 Gy, patient should be treated with the highest achievable dose, or start Treatment with induction chemotherapy if patient had not received induction chemotherapy Repeat Simulation, CT x 2 Immobilization, Weekly AE Motion Assessment, and WkMotion 6 PROs Management, Follow ups sec. 6.3 Wk 4 blood 12
13 Motion Management Strategy example of 4D CT 13
14 Example of Simulation for Breath Hold treatment Does the tumor move enough to justify BH treatment Can the patient follow instructions for a >15 sec BH Does the tumor reproduce to the same position (based on 5 10 repeated video feedback guided breath hold scans) What is the patient specific IM among a series of breath holds P. Balter 14
15 Overall Flow Diagram Radiation Treatment planning RADIATION THERAPY: Refer to protocol sec. 6.0: Sim and motion Target Dose Tumor dose Quick review of the Data submission: Delineation TRIAD management constraints prescriptions plans (5 cases) Dose Specifications, protocol sec. 6.1 as follows: 1. Plan prescription dose 70 Gy, if not meeting dose constraints, Yes 1. Submit the case to RTOG headquarters QA for review and suggestions, if still not meeting dose constraint Adaptive 2. Reduce tumor dose 2 Gy each time, i.e. 68, 66, 64, 62, and 60 till dose constraints Planning? are met. Physics QA Peer review QA 2. If dose constraints can not be met at 60 Gy, patient should be treated with the highest achievable dose, or start with induction chemotherapy if patient had not received induction chemotherapy Treatment Repeat Simulation, CT x 2 Immobilization, Weekly AE Motion Assessment, and WkMotion 6 PROs Management, Follow ups sec. 6.3 Target Definitions, Target Delineation, and Normal Anatomy Delineation, sec 6.4 Required structures should we standardize the color? Wk 4 blood 15
16 Standardization on Colors Structure DICOM Standard Name Gross Tumor Volume GTV RED GTV plus margin for tumor motion IGTV RED Clinical Target Volume CTV YELLOW Internal Target Volume ITV YELLOW Planning Target Volume PTV Spinal Cord SpinalCord Right + Left Lung minus GTV Lungs Right Lung Lung_R Left Lung Lung_L Esophagus Esophagus Brachial Plexus BrachialPlexus Heart Heart Liver Liver Brown Right Kidney Left Kidney Kidney_R Kidney_L Orange 16
17 Proposed DVH Constraints with New Rec on Heart Normal lung (right lung V + left lung V GTV) Per Protocol V20 37%; MLD 20 Gy (RBE); lung V5 60% Variation Acceptable* V20 40 % or MLD 22 Gy (RBE); lung V5 65% Esophagus Max dose: 74 Gy (RBE) 1cc of partial circumference Max dose: 74 Gy (RBE) 1.5 cc of partial circumference V cc V cc V cc V cc V cc V cc V cc V cc Spinal cord*** V50 < 0.03 cc V52< 0.03 cc Brachial plexus** Heart V30 50% V45 35% Max Dose to a point that is 0.03 cc 70 Gy V30 55% V45 40% Max Dose to a point that is 0.03 cc 75 Gy**** 17
18 Plan Review Criteria Cover 95% of the PTV with the prescription dose. <= 0.03 cc inside PTV should exceed 120% of the prescribed dose. Cover 100% of the ITV Variation Acceptable: 95% of the PTV is covered by 95% of the prescription dose, <= 0.03 cc inside the PTV >120% <=125% of the prescribed dose; <=0.03 cc <85% >=75% of the prescription dose; <100% but >=99% of the ITV is covered by the prescription dose Deviation Unacceptable: A Deviation Unacceptable occurs when any of the Variation Acceptable dose limits stated above are not met 18
19 Overall Flow Diagram Radiation Treatment planning Sim and motion management Target Delineation Dose constraints Tumor dose prescriptions Quick review of the plans (5 cases) Yes Adaptive Planning? 4DCT is repeated at the end of week 2 and mid-week 5 QA Anatomy review is performed first Dosimetric review (recalculation of original plan on new anatomy) is requested when Physics QA Peer review there QA is significant changes Replan if necessary Treatment Repeat CT x 2 Weekly AE Wk 4 blood Wk 6 PROs Follow ups 19
20 Overall Flow Diagram Radiation Treatment planning Sim Quick and review motion of the plans Target and replans: Dose Tumor dose management Refer to protocol Delineation constraints prescriptions Case submitted refer to Ying Xiao, presentation for Yes TRIAD system QA PI or designee notified (Liao, Hoppe, Bradley, Adaptive etc) Planning? Feedback send Physics to submitting QA institutionpeer review QA If plan good move to treat the patient If plan needs revision, repeat Treatment above steps Repeat CT x 2 Weekly AE Wk 4 blood Wk 6 PROs Quick review of the (re)plans (3 cases) Follow ups 20
21 Questions? 21
International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO
International RT Clinical Trial Group Membership & Quality Control BY DR YING XIAO Disclosures The Department of Radiation Oncology at Hospital of University of Pennsylvania has a research agreement with
More informationImplementing SBRT Protocols: A NRG CIRO Perspective. Ying Xiao, Ph.D. What is NRG Oncology?
Implementing SBRT Protocols: A NRG CIRO Perspective Ying Xiao, Ph.D. What is NRG Oncology? One of five new NCI-supported National Clinical Trials Network (NCTN) groups. NCTN officially started March 1,
More informationClinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor
Clinical Aspects of Proton Therapy in Lung Cancer Joe Y. Chang, MD, PhD Associate Professor Clinical Service Chief Thoracic Radiation Oncology Lung Cancer Basic Factors No. 1 cancer killer 161,840 patients
More informationNRG ONCOLOGY. RTOG 1308 (ClinicalTrials.gov NCT # )
NRG ONCOLOGY RTOG 1308 (ClinicalTrials.gov NCT #01993810) PHASE III RANDOMIZED TRIAL COMPARING OVERALL SURVIVAL AFTER PHOTON VERSUS PROTON CHEMORADIOTHERAPY FOR INOPERABLE STAGE II-IIIB NSCLC This trial
More informationLeveraging Innovation to Design Future Clinical Trials. Outline. Multi-Institutional Research 7/15/2015
Leveraging Innovation to Design Future Clinical Trials Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A Perez Distinguished Professor of Radiation Oncology Outline National Clinical Trial Network
More informationTreatment Planning & IGRT Credentialing for NRG SBRT Trials
Treatment Planning & IGRT Credentialing for NRG SBRT Trials Hania Al Hallaq, Ph.D. Department of Radiation & Cellular Oncology The University of Chicago Learning Objectives Explain rationale behind credentialing
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationJonathan D Grant *, Angela Sobremonte, Evangeline Hillebrandt, Pamela K Allen and Daniel R Gomez *
Grant et al. Radiation Oncology (2015) 10:32 DOI 10.1186/s13014-015-0332-9 RESEARCH Open Access The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation
More informationNSABP PROTOCOL B-39B RTOG PROTOCOL 0413
NSABP PROTOCOL B-39B RTOG PROTOCOL 0413 (A RANDOMIZED PHASE III STUDY OF CONVENTIONAL WHOLE BREAST IRRADIATION WBI) VERSUS PARTIAL BREAST IRRADIATION (PBI) FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER
More informationMight Adaptive Radiotherapy in NSCLC be feasible in clinical practice?
Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus
More informationRPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy
RPC Liver Phantom Highly Conformal Stereotactic Body Radiation Therapy Guidelines for Planning and Irradiating the RPC Liver Phantom. Revised Dec 2005 Credentialing for this protocol requires four steps:
More informationAllan Price NHS Lothian, Edinburgh, UK
Allan Price NHS Lothian, Edinburgh, UK Radiotherapy Dose Volume Timing Technique PCI Surgery Systemic agents 1 Study Dose Time Induction CT Ann Arbor 65.1-75.6 Gy Duke 73.6-80 Gy RTOG 77.4 Gy 74 Gy 6.5-7.5
More informationDefining Target Volumes and Organs at Risk: a common language
Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce
More informationConflicts of Interest
Dose Constraints to Prevent Radiation-Induced Brachial Plexopathy for Unresectable Lung Cancer Amini A*, Yang J, Williamson R, McBurney ML, Erasmus J, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox
More informationClinical Trial Credentialing:
IROC Mission Clinical Trial Credentialing: Provide integrated radiation oncology and diagnostic Where imaging to Start quality and control programs in support of the NCI s NCTN Network thereby Resources
More informationThis section was clarified to direct questions regarding eligibility to the study data manager.
For Protocol Amendment 8 to: RTOG 0839, Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy in Potentially Operable Locally
More informationSpecification of Tumor Dose. Prescription dose. Purpose
Specification of Tumor Dose George Starkschall, Ph.D. Department of Radiation Physics U.T. M.D. Anderson Cancer Center Prescription dose What do we mean by a dose prescription of 63 Gy? Isocenter dose
More information8/3/2016. Implementation of Pencil Beam Scanning (PBS) Proton Therapy Treatment for Liver Patients. Acknowledgement. Overview
Implementation of Pencil Beam Scanning (PBS) Proton Therapy Treatment for Liver Patients Liyong Lin, PhD, Assistant Professor Department of Radiation Oncology University of Pennsylvania Acknowledgement
More informationASTRO Andrew J. Hope, M.D.
IGRT for lung cancer; does XRT dose escalation improve outcome? Jeffrey Bradley, M.D. Associate Professor Department of Radiation Oncology Washington University and The Alvin J. Siteman Comprehensive Cancer
More informationAshley Pyfferoen, MS, CMD. Gundersen Health Systems La Crosse, WI
Ashley Pyfferoen, MS, CMD Gundersen Health Systems La Crosse, WI 3 Radiation Oncologists 3 Physicists 2 Dosimetrists 9 Radiation Therapists o o o o o o o o o Brachial Plexus Anatomy Brachial Plexopathy
More informationIGRT Solution for the Living Patient and the Dynamic Treatment Problem
IGRT Solution for the Living Patient and the Dynamic Treatment Problem Lei Dong, Ph.D. Associate Professor Dept. of Radiation Physics University of Texas M. D. Anderson Cancer Center Houston, Texas Learning
More informationOutline. Contour quality control. Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT)
Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT) James Kavanaugh, MS DABR Department of Radiation Oncology Division of Medical Physics Outline Importance
More informationPersonalized radiation therapy through functional lung avoidance and response
Personalized radiation therapy through functional lung avoidance and response Adaptive dose escalation (FLARE RT) AAMD Annual Meeting Indianapolis Patricia Sponseller, MS, CMD, RTT, (R)(T) June 14, 2017
More informationASTRO econtouring for Lymphoma. Stephanie Terezakis, MD
ASTRO econtouring for Lymphoma Stephanie Terezakis, MD Disclosures No conflicts to disclose 1970 Total Lymphoid Irradiation (TLI) 1995 Involved-Field Radiotherapy (IFRT) 2008 Involved Node Radiotherapy
More informationStereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors
Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Anna Bruynzeel, Radiation Oncologist VU University Medical Center, Amsterdam, The Netherlands Current standard
More informationAytul OZGEN 1, *, Mutlu HAYRAN 2 and Fatih KAHRAMAN 3 INTRODUCTION
Journal of Radiation Research, 2012, 53, 916 922 doi: 10.1093/jrr/rrs056 Advance Access Publication 21 August 2012 Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationComparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment
Research Article imedpub Journals www.imedpub.com Archives in Cancer Research DOI: 10.21767/2254-6081.100185 Comparison of IMRT and VMAT Plan for Advanced Stage Non-Small Cell Lung Cancer Treatment Abstract
More informationNCI Protocol Version Date: October 11, 2016 (Broadcast: November 7, 2016) The protocol version date was updated
For Protocol Amendment 8 to: RTOG 1106 / ACRIN 6697, Randomized Phase II trial of individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT And Modern Technology in Locally Advanced Non-Small
More informationREVISITING ICRU VOLUME DEFINITIONS. Eduardo Rosenblatt Vienna, Austria
REVISITING ICRU VOLUME DEFINITIONS Eduardo Rosenblatt Vienna, Austria Objective: To introduce target volumes and organ at risk concepts as defined by ICRU. 3D-CRT is the standard There was a need for a
More informationSBRT fundamentals. Outline 8/2/2012. Stereotactic Body Radiation Therapy Quality Assurance Educational Session
Stereotactic Body Radiation Therapy Quality Assurance Educational Session J Perks PhD, UC Davis Medical Center, Sacramento CA SBRT fundamentals Extra-cranial treatments Single or small number (2-5) of
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationRadiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali
Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali Let us keep this simple and stick to some basic rules Patient positioning Must be reproducible Must be
More informationLinac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR
Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationImage Registration for Radiation Therapy Applications: Part 2: In-room Volumetric Imaging
Image Registration for Radiation Therapy Applications: Part 2: In-room Volumetric Imaging Peter Balter Ph.D University of Texas M.D. Anderson Cancer Center Houston, TX, USA Disclosure Information Peter
More informationHot topics in Radiation Oncology for the Primary Care Providers
Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease
More informationBig Data: How VHA Can Be Your Friend
Big Data: How VHA Can Be Your Friend Jatinder R Palta PhD Rishabh Kapoor MS Michael Hagan PhD, MD National Radiation Oncology Program(10P11H) Veterans Health Administration, USA Disclosure Vice President,
More information8/2/2012. Transitioning from 3D IMRT to 4D IMRT and the Role of Image Guidance. Part II: Thoracic. Peter Balter, Ph.D.
8/2/2012 Transitioning from 3D IMRT to 4D IMRT and the Role of Image Guidance Part II: Thoracic Peter Balter, Ph.D. Disclosure Dr. Balter is Physics PI on a trial comparing Cyberknife based SBRT with surgery,
More informationJosh Howard CMD Upendra Parvathaneni MBBS, FRANZCR
Anatomic and Dosimetric Correlation in the Treatment of Advanced Larynx Cancer- When is the Brachial Plexus at Risk? Josh Howard CMD Upendra Parvathaneni MBBS, FRANZCR AAMD 39th Annual Meeting - Seattle
More informationOverview. Proton Therapy in lung cancer 8/3/2016 IMPLEMENTATION OF PBS PROTON THERAPY TREATMENT FOR FREE BREATHING LUNG CANCER PATIENTS
IMPLEMENTATION OF PBS PROTON THERAPY TREATMENT FOR FREE BREATHING LUNG CANCER PATIENTS Heng Li, PhD Assistant Professor, Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, TX, 773
More informationPartial Breast Irradiation using adaptive MRgRT
Partial Breast Irradiation using adaptive MRgRT Shyama Tetar, radiation-oncologist VUmc Amsterdam 15-12-2017 5 th Vumc SBRT symposium 2017 Current practice Breast conserving treatment (BCT) Breast conserving
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationDosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer
Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationFor Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
For Protocol Amendment 3 of: NRG-BR001, A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases NCI/Local Protocol #: NRG-BR001/NRG BR001 NCI Protocol Version
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationStereotaxy. Outlines. Establishing SBRT Program: Physics & Dosimetry. SBRT - Simulation. Body Localizer. Sim. Sim. Sim. Stereotaxy?
Establishing SBRT Program: Physics & Dosimetry Lu Wang, Ph.D. Radiation Oncology Department Fox Chase Cancer Center Outlines Illustrate the difference between SBRT vs. CRT Introduce the major procedures
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More information8/3/2016. Outline. Site Specific IGRT Considerations for Clinical Imaging Protocols. Krishni Wijesooriya, PhD University of Virginia
Site Specific IGRT Considerations for Clinical Imaging Protocols Krishni Wijesooriya, PhD University of Virginia Outline Image registration accuracies for different modalities What imaging modality best
More informationQuestions may be submitted anytime during the presentation.
Understanding Radiation Therapy and its Role in Treating Patients with Pancreatic Cancer Presented by Pancreatic Cancer Action Network www.pancan.org August 18, 2014 If you experience technical difficulty
More informationOn the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors
On the use of 4DCT derived composite CT images in treatment planning of SBRT for lung tumors Zhe (Jay) Chen, Ph.D. Department of Therapeutic Radiology Yale University School of Medicine and Yale-New Haven
More informationCredentialing for Clinical Trials -IGRT. Evidence Based Radiation Oncology. Levels of Clinical Evidence. Why Credentialing?
Acknowledgements Credentialing for Clinical Trials -IGRT Invitation from Organizers RTOG Headquarter QA Team ATC Collaborators Evidence Based Radiation Oncology Clinical Trials From Collaborative Groups
More informationFor Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer
Section For Protocol Amendment 5 of: RTOG 0938, A Randomized Phase II Trial of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer NCI/Local Protocol #: RTOG-0938/RTOG 0938 NCI Protocol Version
More informationThe Physics of Oesophageal Cancer Radiotherapy
The Physics of Oesophageal Cancer Radiotherapy Dr. Philip Wai Radiotherapy Physics Royal Marsden Hospital 1 Contents Brief clinical introduction Imaging and Target definition Dose prescription & patient
More informationDose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed
Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer
More information1 : : Medical Physics, Città della Salute e della Scienza, Torino, Italy
Fusella M. 1, Badellino S. 2, Boschetti A. 1, Cadoni F. 1, Giglioli F. R. 1, Guarneri A. 3, Fiandra C. 2, Filippi A. 2, Ricardi U. 2, Ragona R. 2 1 : : Medical Physics, Città della Salute e della Scienza,
More informationCombined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
More informationWhat is Next for Patients with Stage III Non-Small Cell Lung Cancer?
What is Next for Patients with Stage III Non-Small Cell Lung Cancer? Walter J Curran, Jr, MD Executive Director Winship Cancer Institute of Emory University Atlanta, GA NRG Oncology Group Chairman 1 Stage
More information8/2/2017. Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency. Part III
Improving Dose Prescriptions for Safety, Reporting, and Clinical Guideline Consistency Part III I Das, J Moran, M Langer Keeping Guidelines On Track: The Effect On Clinical Practice of Neglecting Guidelines
More informationESOPHAGEAL CANCER DOSE ESCALATION USING A SIMULTANEOUS INTEGRATED BOOST TECHNIQUE
doi:10.1016/j.ijrobp.2010.10.023 Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 1, pp. 468 474, 2012 Copyright Ó 2012 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see front
More informationSUMMARY OF CHANGES Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10
Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10 RTOG 0239, "A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell
More informationAutomated Plan Quality Check with Scripting. Rajesh Gutti, Ph.D. Clinical Medical Physicist
Automated Plan Quality Check with Scripting Rajesh Gutti, Ph.D. Clinical Medical Physicist Veera.Gutti@BSWHealth.org Outline Introduction - BSW Automation in Treatment planning Eclipse Scripting API Script
More informationSBRT TREATMENT PLANNING: TIPS + TRICKS. Rachel A. Hackett CMD, RT(T)
SBRT TREATMENT PLANNING: TIPS + TRICKS Rachel A. Hackett CMD, RT(T) OUTLINE Brief radiobiology review 3D CRT Tx Planning VMAT Tx Planning Protocols Other Sites Oligomets Spine Liver Kidney Adrenal Gland
More informationNEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah
NEOADJUVANT THERAPY IN CARCINOMA STOMACH Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah NEOADJUVANT THERAPY?! Few believers Limited evidence Many surgeons
More informationCurrent Status of Radiotherapy in Lung Cancer. Zhongxing Liao, M.D. Professor of Radiation Oncology , Guangzhou, China
Current Status of Radiotherapy in Lung Cancer Zhongxing Liao, M.D. Professor of Radiation Oncology 2016-12-13, Guangzhou, China Outline Stage I SBRT: Curative treatment for inoperable patients (LC: 96.5%)
More informationClinical Quality Assurance for Particle Therapy Plus ça même Plus
Clinical Quality Assurance for Particle Therapy Plus ça même Plus Thomas F. DeLaney, MD Medical Director Francis H. Burr Proton Center Massachusetts General Hospital Boston MA Quality Assurance Designed
More information4D Radiotherapy in early ca Lung. Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla
4D Radiotherapy in early ca Lung Prof. Manoj Gupta Dept of Radiotherapy & oncology I.G.Medical College Shimla Presentation focus on ---- Limitation of Conventional RT Why Interest in early lung cancer
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More information8/4/2016. Effect of underdosage and overdosage. Photon versus Proton Therapy: Have we reached the limit? Effect. Tumor Dose.
Effect 8/4/2016 Photon versus Proton Therapy: Have we reached the limit? American Association of Medical Physics Annual Meeting Washington, DC Stephen M Hahn August 4, 2016 Effect of underdosage and overdosage
More informationElekta 2017 Australasian User Meeting 12 th November 2017, Newcastle, NSW
This work aims to compare ITVs defined using 4DCBCT data in two treatment planning systems (TPS) and to assess their impact on planned dose Elekta 2017 Australasian Background: Lung SABR in NT Introduction:
More informationZhengfei Zhu 1,3, Wei Liu 2, Michael Gillin 2, Daniel R Gomez 1, Ritsuko Komaki 1, James D Cox 1, Radhe Mohan 2 and Joe Y Chang 1*
Zhu et al. Radiation Oncology 2014, 9:108 RESEARCH Open Access Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary
More informationQuality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety
Quality ID #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION:
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Principles of Radiation Therapy PRINCIPLES OF RADIATION THERAPY a Treatment with
More informationFiducial-Free Lung Tracking and Treatment with the CyberKnife System: A Non-Invasive Approach
Fiducial-Free Lung Tracking and Treatment with the CyberKnife System: A Non-Invasive Approach Jesse McKay, MS, DABR Erlanger Health System Chattanooga, TN JASTRO 2014, Yokohama Japan Disclosure I have
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMedikal Fizik Çalışmaları
Medikal Fizik Çalışmaları Zeynep Özen Acıbadem Altunizade Hastanesi Major Themes Treatment Planning and Delivery (in SRS/SBRT) Improving Quality and Consistency in Clinical Trials via Knowledge- Based
More informationLung Spine Phantom. Guidelines for Planning and Irradiating the IROC Spine Phantom. MARCH 2014
Lung Spine Phantom Guidelines for Planning and Irradiating the IROC Spine Phantom. MARCH 2014 The study groups are requesting that each institution keep the phantom for no more than 2 week. During this
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationTHE TRANSITION FROM 2D TO 3D AND TO IMRT - RATIONALE AND CRITICAL ELEMENTS
THE TRANSITION FROM 2D TO 3D AND TO IMRT - RATIONALE AND CRITICAL ELEMENTS ICTP SCHOOL ON MEDICAL PHYSICS FOR RADIATION THERAPY DOSIMETRY AND TREATMENT PLANNING FOR BASIC AND ADVANCED APPLICATIONS March
More informationA Dosimetric Comparison of Whole-Lung Treatment Techniques. in the Pediatric Population
A Dosimetric Comparison of Whole-Lung Treatment Techniques in the Pediatric Population Corresponding Author: Christina L. Bosarge, B.S., R.T. (R) (T) Indiana University School of Medicine Department of
More informationReport of ICRU Committee on Volume and Dose Specification for Prescribing, Reporting and Recording in Conformal and IMRT A Progress Report
Report of ICRU Committee on Volume and Dose Specification for Prescribing, Reporting and Recording in Conformal and IMRT A Progress Report Paul M. DeLuca, Jr. 1, Ph.D., Vincent Gregoire 2, M.D., Ph.D.,
More informationDOSE AND VOLUME REDUCTION FOR NORMAL LUNG USING INTENSITY-MODULATED RADIOTHERAPY FOR ADVANCED-STAGE NON SMALL-CELL LUNG CANCER
doi:10.1016/j.ijrobp.2003.09.086 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1258 1267, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationDevelopment of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey.
Development of an Expert Consensus Target Delineation Atlas for Thymic Cancers: Initial Quantitative Analysis of an Expert Survey. Charles R. Thomas, Jr., MD, Jayashree Kalpathy-Cramer, PhD, Jehee Choi,
More informationART for Cervical Cancer: Dosimetry and Technical Aspects
ART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray, Ph.D. Radiation Therapy Physics Princess Margaret Cancer Centre/Techna/Ontario Cancer Institute Professor Departments of Radiation
More informationIs the Nodule Malignant? Douglas Arenberg, MD, University of Michigan Health System, Ann Arbor, Michigan
Questions were posed by attendees throughout the meeting using the interactive online question and answer platform. Some questions were addressed during the session, and some of our faculty were able to
More informationWhat do we Know About Adaptive Radiotherapy? Lei Dong, Ph.D. Scripps Proton Therapy Center San Diego, California
What do we Know About Adaptive Radiotherapy? Lei Dong, Ph.D. Scripps Proton Therapy Center San Diego, California AAMD Region II Meeting Houston, Texas September 13-14, 2012 Learning Objectives To gain
More informationLung Cancer Radiotherapy
Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think
More informationReena Phurailatpam. Intensity Modulated Radiation Therapy of Medulloblastoma using Helical TomoTherapy: Initial Experience from planning to delivery
Intensity Modulated Radiation Therapy of Medulloblastoma using Helical TomoTherapy: Initial Experience from planning to delivery Reena Phurailatpam Tejpal Gupta, Rakesh Jalali, Zubin Master, Bhooshan Zade,
More informationVariable Dose Rate Dynamic Conformal Arc Therapy (DCAT) for SABR Lung: From static fields to dynamic arcs using Monaco 5.10
Variable Dose Rate Dynamic Conformal Arc Therapy (DCAT) for SABR Lung: From static fields to dynamic arcs using Monaco 5.10 Simon Goodall Radiation Oncology Physicist Genesis Care Western Australia Introduction
More informationCarbon Ion Radiotherapy for Skull Base and Paracervical Chordomas
Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas Azusa Hasegawa, Jun-etsu Mizoe and Hirohiko Tsujii Research Center Hospital for Charged Particle Therapy National Institute of Radiological
More informationMeasure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety
Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
More informationSBRT I: Overview of Simulation, Planning, and Delivery
Disclosure SBRT I: Overview of Simulation, Planning, and Delivery I have received research funding from NIH, the Golfers Against Cancer (GAC) foundation, and Philips Health System. Jing Cai, PhD Duke University
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More information